Juno Therapeutics, Inc. (NASDAQ:JUNO) gapped up prior to trading on Friday . The stock had previously closed at $41.42, but opened at $41.27. Juno Therapeutics shares last traded at $42.45, with a volume of 2,663,260 shares traded.

Several equities research analysts have issued reports on JUNO shares. Leerink Swann restated an “outperform” rating on shares of Juno Therapeutics in a report on Monday, June 12th. Vetr upgraded Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price target for the company in a report on Monday, August 14th. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 28th. Morgan Stanley increased their price target on Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a report on Monday, August 7th. Finally, Raymond James Financial, Inc. upgraded Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target for the company in a report on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company’s stock. Juno Therapeutics presently has an average rating of “Hold” and a consensus target price of $31.86.

The firm has a 50-day moving average of $30.36 and a 200-day moving average of $25.83. The stock’s market capitalization is $4.40 billion.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same period in the previous year, the firm earned ($0.64) earnings per share. The business’s quarterly revenue was down 22.8% on a year-over-year basis. Equities analysts anticipate that Juno Therapeutics, Inc. will post ($3.12) EPS for the current fiscal year.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,869 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $39.95, for a total transaction of $514,116.55. Following the completion of the sale, the executive vice president now directly owns 50,289 shares of the company’s stock, valued at approximately $2,009,045.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anthony B. Evnin acquired 9,000 shares of the firm’s stock in a transaction on Tuesday, June 20th. The shares were bought at an average cost of $24.40 per share, with a total value of $219,600.00. Following the completion of the acquisition, the director now directly owns 66,301 shares in the company, valued at approximately $1,617,744.40. The disclosure for this purchase can be found here. Insiders sold a total of 8,066,369 shares of company stock valued at $218,108,557 over the last ninety days. 15.26% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the company. Broadfin Capital LLC raised its stake in shares of Juno Therapeutics by 49.2% in the second quarter. Broadfin Capital LLC now owns 262,100 shares of the biopharmaceutical company’s stock worth $7,834,000 after buying an additional 86,400 shares in the last quarter. Wasatch Advisors Inc. bought a new stake in shares of Juno Therapeutics during the second quarter worth approximately $19,787,000. Public Employees Retirement System of Ohio raised its stake in shares of Juno Therapeutics by 115.3% in the second quarter. Public Employees Retirement System of Ohio now owns 56,326 shares of the biopharmaceutical company’s stock worth $1,684,000 after buying an additional 30,170 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Juno Therapeutics by 809,500.0% in the second quarter. Tower Research Capital LLC TRC now owns 16,192 shares of the biopharmaceutical company’s stock worth $484,000 after buying an additional 16,190 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares in the last quarter. 70.76% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/02/juno-therapeutics-inc-juno-shares-gap-up-to-41-27-2.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.